Nitrogen-containing heterocyclic compound
By developing a completely new structure of IRAK4 inhibitor compound, the problem that the prior art is difficult to effectively inhibit IRAK4 kinase activity is solved, and effective treatment of abnormal expression-mediated diseases of IRAK4 is achieved, which significantly reduces the inflammatory response.
Patent Information
- Application Number
- CN202411061179.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-02
AI Technical Summary
Existing treatment methods are difficult to effectively prevent or treat diseases mediated by IRAK4, such as rheumatoid arthritis, lupus erythematosus and other autoimmune diseases, and these diseases are related to abnormal inflammatory signaling, and the prior art is difficult to effectively inhibit the activity of IRAK4 kinase. .
A new class of IRAK4 inhibitor compounds developed through specific synthetic routes such as the use of (7R,7aS)-7-ethyl-3,3-dimethyltetrahydropyrrole[1,2-c]oxazole Compounds such as -5(1H)-one are prepared to prepare effective IRAK4 inhibitors for preparation of pharmaceutical compositions to prevent or treat diseases mediated by abnormal expression of IRAK4.
This compound has a significant inhibitory effect on IRAK4 kinase and can effectively prevent or treat diseases mediated by abnormal expression of IRAK4, including autoimmune diseases such as rheumatoid arthritis and lupus erythematosus, significantly downregulate IRAK4 activity and reduce inflammatory response.
Smart Images

Figure CN118978508A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a novel IRAK4 inhibitor compound and use of the compound in preventing or treating IRAK4-mediated diseases. Background Art
[0002] Chronic inflammatory and autoimmune diseases threaten the lives of millions of people worldwide and are associated with abnormal signaling mediated by inflammation. In addition, some diseases, such as type 2 diabetes and cardiovascular disease, are also associated with abnormal signaling mediated by inflammation.
[0003] Interleukin-1 receptor-associated kinase 4 (IRAK4) is a member of the intracellular serine-threonine kinase IRAK family. Other members of the kinase family include IRAK2, IRAK-M and IRAK3. When the interleukin-1 receptor (IL-1R) or Toll-like receptor (TLR) binds to the ligand, IRAK4 can mediate signal transduction and activate the expression of downstream inflammatory factors. TLRs can receive ligand signals generated by the interaction between the body and microorganisms or endogenous substances, as well as the first wave of inflammatory signals and innate immune response signals triggered by these stimuli. TLRs play a very important role in many diseases, including infections and autoinflammatory diseases, as well as many other diseases in humans. Like tumor necrosis factor-α (TNF-α) and other major cytokines, interleukin-1 (IL-1) is a key factor in the inflammatory pathway that can propagate and amplify signals. Since the signaling pathways mediated by TLR, IL-1R and other cytokine receptors have a cross-linking effect, IRAK4, a key signaling factor downstream of the TLR and IL-1R inflammatory pathways, plays an important role in systemic inflammatory responses and can serve as an effective potential target for the treatment of various inflammation-related diseases. Summary of the invention
[0004] The present invention provides a class of IRAK4 inhibitor compounds with a new structure, uses thereof and pharmaceutical compositions containing the same. The compounds have a better inhibitory effect on IRAK4 kinase.
[0005] The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof:
[0006]
[0007] Among them, R 1 C 1-3 Alkyl, R 2 is halogen or H;
[0008] Preferably, R 1 is methyl or ethyl, R 2 It is H or F.
[0009] The compound represented by formula (I) or a pharmaceutically acceptable salt thereof may be the following compound:
[0010]
[0011] The present invention also provides use of the above compound or a pharmaceutically acceptable salt thereof in preparing an IRAK4 inhibitor.
[0012] The present invention also provides the use of the above compound or a pharmaceutically acceptable salt thereof in preparing a medicament, wherein the medicament is used for preventing or treating a disease mediated by abnormal expression of IRAK4.
[0013] The “diseases mediated by abnormal expression of IRAK4” include, but are not limited to, autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, activated B-cell-like diffuse large B-cell lymphoma, chronic lymphocytic leukemia, relapsed non-Hodgkin's lymphoma and other lymphomas.
[0014] The present invention also provides a pharmaceutical composition, which comprises the above compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0015] As used herein, the term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a compound of the present invention.
[0016] As used herein, the term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the mammals to be treated therewith.
[0017] Certain compounds in the present invention have chiral carbon atoms, double bonds, carbocyclic rings or heterocyclic rings, and the resulting configurational isomers {optical isomers (e.g., enantiomers, diastereomers, etc.), cis-trans isomers, etc.} and mixtures thereof (e.g., racemates) are all within the scope of protection of the present invention. When certain compounds in the present invention indicate a specific configuration, it means that the configurational isomer exists and is substantially free of other isomers.
[0018] As used herein, the term "inhibitor" refers to a molecule that decreases, blocks, prevents, delays activation, inactivates, desensitizes, or downregulates, for example, a gene, protein, ligand, receptor, or cell.
[0019] As used herein, the term "abnormal expression of IRAK4" refers to an increase in IRAK4 activity caused by signaling through IRAK4. DETAILED DESCRIPTION
[0020] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0021] Example 1
[0022]
[0023] A solution of (7R,7aS)-7-ethyl-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(1H)-one (300 mg, 1.73 mmol) and Lawesson's reagent (350 mg, 0.86 mmol) in toluene (10 mL) was heated to reflux for 16 hours. The reaction solution was cooled to room temperature and concentrated. The residue was separated and purified by flash chromatography (ethyl acetate / petroleum ether = 0-50%) to obtain 0002A (100 mg, 29% yellow solid). LCMS (ESI) [M+H] + = 200.2 @ 1.708 min (LC-MS method B).
[0024] A solution of 0002A (100 mg, 0.5 mmol) and iodomethane (355 mg, 2.5 mmol) in acetonitrile (5 mL) was stirred at 25°C for 16 hours. The reaction solution was concentrated to give 0002B (87 mg, 99% yellow solid). LCMS (ESI) [M+H] + = 174 (LC-MS method A).
[0025] Cesium carbonate (488 mg, 1.5 mmol) was added to a solution of 0002B (86 mg, 0.5 mmol) and 0006G (109 mg, 0.5 mmol) in dimethyl sulfoxide (3 mL), and the mixture was heated to 85°C for 16 hours. The reaction solution was extracted with ethyl acetate (10 mL × 2), and the organic phase was washed with water (10 mL × 3) and saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was separated and purified by flash chromatography (ethyl acetate / petroleum ether = 0-50%) to obtain 0002C (40 mg, 22% yellow solid). LCMS (ESI) [M+H] + =356.1@1.296 min (LC-MS method A).
[0026] Potassium carbonate (69 mg, 0.5 mmol) was added to a solution of 0002C (35 mg, 0.1 mmol) in dimethyl sulfoxide (1 mL). The reaction solution was cooled to 10 °C and stirred for 5 minutes. Hydrogen peroxide (0.5 mL, 30%) was slowly added and reacted at room temperature for 10 minutes. Water was added to quench the reaction, and the mixture was extracted with ethyl acetate (10 mL × 2). The organic phase was washed with water (10 mL × 3) and saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated. 0002D (37 mg, 99%) was obtained and used directly in the next step without purification. LCMS (ESI) [M+H] + =374.1@1.69 min (LC-MS method B).
[0027] A solution of 0002D (37 mg, 0.1 mmol) and cyanamide (42 mg, 10 mmol) in ethanol (2 mL) was reacted at room temperature for 16 hours, concentrated, and the residue was separated and purified by flash chromatography (methanol / dichloromethane = 0-8%) to obtain SB-0002 (30 mg, 82% white solid). LCMS (ESI) [M+H] + =368.2@5.716min(Method D). 1 HNMR (400 MHz, DMSO-d 6 )δ9.623(bs,1H),8.182(s,1H),7.922(d,J=5.6Hz,1H),7.855(bs,1H),7.720(bs,1H),7.454-7.467(m,2H),4.432-4.570(m,2H) ,4.246(s,1H),3.990(s,3H),2.990-3.023(m,1H),2.401-2.680(m,2H),1.574-1.639(m,1H),1.365-1.432(m,1H),0.938(t,3H).
[0028] Example 2
[0029]
[0030] A solution of (S)-5-(Hydroxymethyl)pyrrolidin-2-one (3.45 g, 30 mmol), 2,2-dimethoxypropane (6.24 g, 60 mmol) and p-toluenesulfonic acid (190 mg, 1 mmol) in toluene (50 mL) was heated to reflux for 16 hours and then cooled to room temperature. The reaction solution was concentrated and the residue was separated and purified by flash chromatography (methanol / dichloromethane = 0-20%) to obtain 0006A (4.4 g, 94%, yellow oil). LCMS (ESI) [M+H] + =156.2@1.17min (Method A).
[0031] A solution of 0006A (1.55 g, 10 mmol) and Lawesson's reagent (2.02 g, 5 mmol) in toluene (20 mL) was heated to reflux for 16 hours and then cooled to room temperature. The reaction solution was concentrated and the residue was separated and purified by flash chromatography (ethyl acetate / petroleum ether = 0-50%) to obtain 0006B (250 mg, 15%, white solid). LCMS (ESI) [M+H] + =172.2@1.38min (Method B).
[0032] A solution of 0006B (171 mg, 1 mmol) and iodomethane (1.42 g, 10 mmol) in acetonitrile (10 mL) was reacted at 25°C for 16 hours. The reaction solution was concentrated to give 0006C (145 mg, 99%, white solid). LCMS (ESI) [M+H] + =146.1@0.97min (Method B).
[0033] Add 2,2-dimethoxyethane-1-amine (4.7 g, 45 mmol) to a toluene (150 mL) solution of 4-bromo-3-methoxybenzaldehyde (6.45 g, 30 mmol), heat the reaction solution to reflux for 4 hours, and separate the generated water with a water separator. Cool to 0°C, keep the internal temperature below 5°C, add trifluoroacetic anhydride (12 mL, 90 mmol) and boron trifluoride ether (11.1 mL, 90 mmol) solution in sequence, warm to room temperature and continue to react for 16 hours. Pour the reaction solution into a mixture of ice and ammonia water, extract with ethyl acetate (200 mL×3), wash the organic phase with water and saturated brine in sequence, dry over anhydrous sodium sulfate, filter and concentrate, and separate and purify the residue by flash chromatography (ethyl acetate / petroleum ether=1 / 1) to obtain 0006D (4.7 g, 66%, dark brown solid). LCMS (ESI) [M+H] + =238.1@1.71min (Method B).
[0034] A solution of 0006D (1.5 g, 6.3 mmol), zinc powder (41 mg, 0.63 mmol), zinc cyanide (1.158 g, 9.9 mmol), 1,1'-bis(diphenylphosphino)ferrocene (35 mg, 0.063 mmol), (dibenzylacetone)dipalladium (0) (29 mg, 0.315 mmol) in N,N-dimethylacetamide (12 mL) was heated to 150°C and microwaved for 1.5 hours. The reaction solution was filtered, and water was added to the filtrate. Solids precipitated, filtered, and the filter cake was dried to obtain 0006E (1.1 g, 94%, yellow solid). LCMS (ESI) [M+H] + =185.1@1.40min (Method B).
[0035] 3-Chloroperoxybenzoic acid (1.547 g, 8.97 mmol) was added to a solution of 0006E (1.1 g, 5.98 mmol) in dichloromethane (20 mL) and reacted at room temperature for 16 hours. Water was added to the reaction solution, extracted with dichloromethane (20 mL × 2), and the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain 0006F (1.2 g, 99%, yellow solid), which was used directly in the next step without purification. LCMS (ESI) [M+H] + =201.1@1.05min (Method B).
[0036] The mixture of 0006F (1.2 g, 6 mmol) and phosphorus oxychloride (10 mL) was heated to 105°C for 2 hours. The reaction solution was concentrated to dryness, and the residue was washed with saturated sodium bicarbonate solution (10 mL×2) and dried to obtain 0006G (850 mg, 64%, light yellow solid). LCMS (ESI) [M+H] + =219.0@1.86min (Method A).
[0037] Potassium carbonate (69 mg, 0.5 mmol) and hydrogen peroxide (0.2 mL, 30%) were added to a solution of 0006G (22 mg, 0.1 mmol) in dimethyl sulfoxide (1 mL), and the mixture was reacted at room temperature for 30 minutes. Water was added to quench the reaction, and the reaction solution was extracted with ethyl acetate (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to obtain 0006H (24 mg, 99%, yellow solid), which was used directly in the next step without purification. LCMS (ESI) [M+H] + =237.0@1.38min.(Method A).
[0038] At -10°C, potassium bis(trimethylsilyl)amide (0.5M / toluene, 1 mL, 0.5 mmol) was added to a solution of 0006H (24 mg, 0.1 mmol) and 0006C (15 mg, 0.1 mmol) in dry N,N-dimethylformamide (2 mL), and the reaction solution was heated to room temperature and stirred for 4 hours. The reaction solution was extracted with ethyl acetate (10 mL×2), and the organic phase was washed with water (10 mL×3) and saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by flash chromatography (methanol / dichloromethane=0-10%) to obtain 0006I (20 mg, 57%, yellow solid). LCMS (ESI) [M+H] + =346.2@1.47min (Method B).
[0039] A solution of 0006I (20 mg, 0.058 mmol) and cyanamide (24 mg, 0.58 mmol) in ethanol (3 mL) was reacted at room temperature for 16 hours. The reaction solution was concentrated, and the residue was separated and purified by flash chromatography (methanol / dichloromethane = 0-7%) to obtain a crude product, which was further purified by Pre-HPLC (Column Xbridge 21.2*250mm C18, 10um, mobile phase A: water (10mmol / L ammonium bicarbonate) B: acetonitrile). SB-0006 (3 mg, 15%, white solid) was obtained. LCMS (ESI) [M+H] + =340.2@4.71min (Method D). 1 HNMR (400MHz, CD 3 OD)δ8.421(s,1H),7.921(d,J=5.6Hz,1H),7.690(s,1H),7.388(d,J=5.6Hz,1H),4.554-4.641(m,2H) ,4.444-4.474(m,1H),3.119(s,3H),2.932-3.151(m,2H),2.508-2.559(m,1H),2.217-2.232(m,1H).
[0040] Example 3
[0041]
[0042] A solution of (3S,4S,5S)-4-ethyl-3-fluoro-5-(hydroxymethyl)pyrrolidin-2-one (160 mg, 1 mmol), 2,2-dimethoxypropane (208 mg, 2 mmol) and p-toluenesulfonic acid (6 mg, 0.03 mmol) in toluene (50 mL) was heated to reflux for 16 hours and then cooled to room temperature. The reaction solution was concentrated and the residue was separated and purified by flash chromatography (methanol / dichloromethane = 0-20%) to obtain 0011A (160 mg, 80%, yellow oil). LCMS (ESI) [M+H] + =202.2@1.31min (Method B).
[0043] A solution of 0011A (0.2 g, 1 mmol) and Lawesson's reagent (202 mg, 0.5 mmol) in toluene (10 mL) was heated to reflux for 4 hours and then cooled to room temperature. The reaction solution was concentrated and the residue was separated and purified by flash chromatography (ethyl acetate / petroleum ether = 0-50%) to obtain 0011B (120 mg, 55%, yellow oil). LCMS (ESI) [M+H] + =218.1@1.83min (Method A).
[0044] A solution of 0011B (120 mg, 0.55 mmol) and iodomethane (780 mg, 5.5 mmol) in acetonitrile (5 mL) was reacted at 25°C for 16 hours. The reaction solution was concentrated to give 0011C (105 mg, 99%, white solid). LCMS (ESI) [M+H] + =192.1@1.34min (Method B).
[0045] At -10°C, potassium bis(trimethylsilyl)amide (0.5M / toluene, 2.1mL, 1.05mmol) was added to a solution of 0006H (62mg, 0.26mmol) and 0011C (50mg, 0.26mmol) in dry N,N-dimethylformamide (2mL), and the reaction solution was heated to 25°C for 4 hours. The mixture was extracted with ethyl acetate (10mL×3), and the organic phase was washed with water (10mL×3) and saturated brine (10mL), dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by flash chromatography (methanol / dichloromethane=0-6%) to obtain 0011D (100mg, 97%, yellow solid). LCMS (ESI) [M+H] + =392.1@1.68min (Method B).
[0046] A solution of 0011D (100 mg, 0.255 mmol) and cyanamide (107 mg, 2.55 mmol) in ethanol (5 mL) was reacted at room temperature for 16 hours. The reaction solution was concentrated and the residue was purified by preparative Pre-HPLC (Column Xbridge 21.2*250 mm C18, 10 um, mobile phase A: water (10 mmol / L ammonium bicarbonate) B: acetonitrile). SB-0011 (2 mg, 2%, white solid) was obtained. LCMS (ESI) [M+H] + =386.2@6.15min (Method D). 1 HNMR (400MHz, CD 3 OD)δ8.375(s,1H),7.941(d,J=5.6Hz,1H),7.498(s,1H),7.421(d,J=5.6Hz,1H),4.776-4.852(m,1H) ,4.391-4.499(m,2H),4.135(s,3H),2.787-2.862(m,2H),1.700-1.772(m,2H),1.109-1.145(m,3H).
[0047] Attached analysis method
[0048] 1 H NMR and 19F NMR spectra were detected on a Bruker AVIII400.
[0049] LCMS was performed on an Agilent 1200HPLC / 6100SQ system using the following conditions:
[0050] Method A: Mobile phase: A: water (0.01% TFA) B: acetonitrile (0.01% TFA); Gradient phase: 5% B increase to 95% B within 1.4 min, 95% B with 1.6 min (total running time: 3 min); Flow rate: 2.3 mL / min; Column type: SunFire C18, 4.6*50 mm, 3.5 μm; Column temperature: 50°C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), ES-API.
[0051] Method B: Mobile phase: A: Water (10 mM NH 4 HCO 3 )B: acetonitrile; gradient phase: 10% to 95% B within 1.5 min, 95% B with 1.5 min (total running time: 3 min); flow rate: 1.8 mL / min; column type: XBridge C18, 4.6*50 mm, 3.5 um; column temperature: 50°C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), MSD (ES-API).
[0052] Method C: Mobile phase: A: water (0.01% TFA) B: acetonitrile (0.01% TFA); Gradient phase: 5% B increase to 95% B within 1.2 min, 95% B with 13.8 min (total running time: 15 min); Flow rate: 2 mL / min; Column type: SunFire C18, 4.6*50 mm, 3.5 μm; Column temperature: 50°C. Detectors: UV (214 nm and 4 nm), MS (ESI, Posmode, 132 to 1500 amu).
[0053] Method D: Mobile phase: A: Water (10 mM NH 4 HCO 3)B: acetonitrile; gradient phase: 10% to 95% B within 8 min, 95% B with 7 min (total running time: 15 min); flow rate: 1 mL / min; column type: XBridge C18, 4.6*50 mm, 3.5 um; column temperature: 40°C. Detector: UV (214 nm and 4 nm), MS (ESI, Pos mode, 132 to 1500 amu).
[0054] Method E: Mobile phase: A: water (0.01% TFA) B: acetonitrile (0.01% TFA); Gradient phase: 5% B increase to 95% B within 1.2 min, 95% B for 1.8 min, back to 5% B within 0.01 min. (Total running time: 15 min); Flow rate: 2 mL / min; Column type: SunFire C18, 4.6*50 mm, 3.5 μm; Column temperature: 40°C. Detector: UV (214 nm and 4 nm), MS (ESI, Pos mode, 132 to 1500 amu).
[0055] Effect Example IRAK4 kinase activity inhibition detection
[0056] Detection of IC of IRAK4 kinase 50 Staurosporine was used as a positive control compound. This experiment used the mobility shift assay to screen compounds on IRAK4 kinase.
[0057] Preparation of compound concentration gradient: the starting concentration of the test compound is 10 μM, 4-fold dilution, 10 concentrations, and duplicate well detection. Gradient dilution is performed in a 384-well plate to form 10 solutions of different concentrations of 100 times the final concentration. Then 250 nL is transferred to the 384 reaction plate using a pipetting system (Labcyte, Echo550) for use. 250 nL of 100% DMSO is added to the negative control well and the positive control well, respectively. A kinase (Carna, 09-145) solution of 2.5 times the final concentration is prepared using kinase buffer (prepared by Sandia Pharmaceutical Technology (Shanghai) Co., Ltd.). 10 μL of 2.5 times the final concentration of kinase solution is added to the compound well and the positive control well (Staurosporine, selleckchem, S1421), respectively; 10 μL of kinase buffer is added to the negative control well. Centrifuge at 1000 rpm for 30 seconds, shake and mix, and incubate at room temperature for 10 minutes. Use kinase buffer to prepare a mixed solution of ATP (Sigma, A2383) and substrate (Kinase substrate 8, GL, 112396) at 25 / 15 times the final concentration. Add 15 μL of a mixed solution of ATP and substrate at 25 / 15 times the final concentration to start the reaction. Centrifuge the 384-well plate at 1000 rpm for 30 seconds, shake and mix, and incubate at room temperature for the corresponding time. Add 30 μL of stop detection solution (prepared by Sandia Pharmaceutical Technology (Shanghai) Co., Ltd.) to stop the kinase reaction, centrifuge at 1000 rpm for 30 seconds, and shake and mix. Read the conversion rate using a microplate reader (Caliper EZ ReaderⅡ).
[0058] Data Analysis:
[0059] Calculation formula:
[0060]
[0061] %Inhibition is the inhibition rate; Conversion%_sample is the conversion rate reading of the sample;
[0062] Conversion%_min: Mean value of negative control wells, representing the conversion rate readings of wells without enzyme activity;
[0063] Conversion%_max: The mean ratio of the positive control wells, representing the conversion rate reading of the wells without compound inhibition.
[0064] Fitting dose-effect curve:
[0065] The log value of the concentration was used as the X-axis, and the percentage inhibition rate was used as the Y-axis. The log (inhibitor) vs. response-Variable slope of the analysis software GraphPad Prism 5 was used to fit the dose-effect curve to obtain the IC50 value of each compound on the enzyme activity. The calculation formula is as follows: Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC 50 -X)*HillSlope)), the results are shown in Table 1:
[0066] Table 1
[0067] Compound No. <![CDATA[IC 50 (nM)]]> SB-0002 0.84 SB-0006 1.77 SB-0011 0.94
Claims
1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: in, R 1 C 1-3 Alkyl, R 2 is halogen or H.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, R 1 is methyl or ethyl, R 2 It is H or F.
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, which is:
4. A pharmaceutical composition comprising the compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
5. Use of the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof, in the preparation of an IRAK4 kinase inhibitor.
6. The use as claimed in claim 5, comprising autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, activated B-cell-like diffuse large B-cell lymphoma, chronic lymphocytic leukemia, relapsed non-Hodgkin's lymphoma and other lymphomas.
Citation Information
Patent Citations
Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
CN106458912A
Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
CN107949559A
IRAK4 inhibitors and uses thereof
CN111542516A
